Background: Pseudohypoparathyroidism (PHP) indicates a group of heterogeneous disorders whose common feature is represented by impaired signaling of hormones that activate Gsalpha, encoded by the imprinted GNAS gene. PHP-Ib patients have isolated Parathormone (PTH) resistance and GNAS epigenetic defects while PHP-Ia cases present with hormone resistance and characteristic features jointly termed as Albright's Hereditary Osteodystrophy (AHO) due to maternally inherited GNAS mutations or similar epigenetic defects as found for PHP-Ib. Pseudopseudohypoparathyroidism (PPHP) patients with an AHO phenotype and no hormone resistance and progressive osseous heteroplasia (POH) cases have inactivating paternally inherited GNAS mutations.
Introduction
Heterozygous inactivating mutations affecting the GNAS gene have been reported to cause Albright's Hereditary Osteodystrophy (AHO, MIM 300800), a complex and broad phenotype mostly characterized by short stature, obesity, round face, subcutaneous calcifications, brachydactyly and cognitive impairment [1] [2] [3] [4] . Patients carrying GNAS loss-of-function mutations on maternally inherited alleles have pseudohypoparathyroidism type Ia (PHP-Ia, MIM 103580) that is characterized by AHO and resistance to multiple stimulatory G protein-coupled hormones (e.g. Parathormone (PTH) and others) [5] [6] [7] [8] [9] [10] , while patients with paternally inherited GNAS mutations are reported as having only AHO features or pseudopseudohypoparathyroidism (PPHP) ( Table 1 ) [2, 4, 11, 12] . Progressive Osseous Heteroplasia (POH, MIM 166350) describes a severe disease characterized by ectopic bone formation that affects not only the subcutis, but also the skeletal muscle and the deep connective tissue. POH is considered as an extreme variant of PPHP that can be associated with some AHO features and is also caused by paternally inherited GNAS inactivating mutations (Table 1) [13] . GNAS imprinting defects have extensively been described in pseudohypoparathyroidism type Ib (PHP-Ib, MIM 623233) patients [11, 14] with hormone resistance to PTH and TSH only and having no AHO. However, recent studies have shown the presence of epigenetic GNAS defects in PHP-Ia patients without mutations in the GNAS coding region ( Table 1 ) [15] [16] [17] [18] [19] . These findings suggest a reclassification of PHP-Ia and PHP-Ib patients as extreme ends of one heterogeneous group of GNAS (epi)genetic defects. The latter is further supported by the Gs functional overlapping between PHP-Ia and PHP-Ib recently reported, where Gsalpha hypofunction, determined either in isolated erythrocyte membranes or in platelets, has been detected also in patients with GNAS imprinting mutations, AHO features and hormone resistance [15, 20, 21] . Gsalpha loss of function is also a finding in PPHP patients [20, 22, 23] . However, despite the fact that large-scale studies showed an association between AHO phenotype and loss of Gs activity [22, [24] [25] [26] , only a small number of PPHP subjects have inactivating GNAS mutations. The severity of the AHO phenotype varies greatly between patients, and some patients have only few features of the syndrome.
Some clinical characteristics of AHO are also reported in imprinting syndromes Silver-Russell, Beckwith-Wiedemann, Prader-Willi and Angelman that are mainly characterized by defects in growth, behaviour and/or development. To further support the common soil of imprinting disorders, an 'imprinting gene network' that regulates embryonic growth and differentiation dependent on Zac-1 (also known as pleiomorphic adenoma gene-like 1 (PLAGL1)) regulation has been identified [27] . A subset of imprinting genes has been found to influence growth progression via coordination of the glucose-regulated metabolism [28] . Among those genes, together with GNAS also the IGF2/H19 cluster and the SNURF/SNRPN regions have been described to play a causative role in embryonic growth defects. DNA methylation defects involving imprinting control region 1 (ICR1) of the IGF2/ H19 locus for which methylation abnormalities result in two growth disorders with opposite phenotypes: the overgrowth disorder Beckwith-Wiedemann syndrome [29] with maternal H19-ICR1 hypermethylation and the growth retardation disorder Silver-Russell syndrome [30] with paternal H19-ICR1 loss of methylation. Prader-Willi and Angelman syndromes [31] are distinct neurodevelomental disorders that are associated with the deletion of the chromosomal 15q11-13 region, loss of imprinting or uniparental disomy of chromosome 15. The SNURF/SNRPN region is hypermethylated in some Prader-Willi syndrome patients [31] .
We here study the methylation of the growth regulatory imprinted genes GNAS (NESP, XL and ExonA/B amplicons), IGF2/H19 and SNURF in 17 patients with some typical AHO features that mainly include in common growth retardation and brachydactyly. Methylation studies of GRB10 are also performed, as the imprinting of this gene is not actually linked to growth regulation but rather to behaviour [32] . All 13 patients that were available for platelet Gs testing showed a significant platelet Gs hypofunction but they did not carry GNAS coding mutations.
Materials and Methods

Ethics Statement
Verbal informed consent to collect blood samples for advanced non-routine diagnostic procedures was obtained from the participants and/or their legal representatives. This strategy is in agreement with the Belgian Law and local regulations and was specifically approved for this study by the Ethics Committee of the Katholieke Universiteit Leuven-University of Leuven. The Ethics Committee of the Katholieke Universiteit Leuven-University of Leuven, also waived the need for formal approval by the ethical review board.
Participants
Patients enrolled in this study were followed at or referred to the pediatric endocrinology department of the University Hospital in Leuven (Belgium).
Patients were selected based on having AHO features, mostly with severe short stature, mental retardation or behavioural problems, clinodactyly or short metacarpals. Few patients also showed obesity and none of them presented with subcutaneous calcifications. One patient (patient 5) showed heterotopic ossifications, and was diagnosed with Progressive Osseous Heteroplasia [33, 34] . Other clinical characteristics were also present and are reported in Table 2 . None of the patients had abnormal PTH, calcium or phosphate values.
Functional platelet Gs pathway test
The platelet aggregation-inhibition test was performed as described [35] [36] [37] [38] . Samples were processed within 3 hours after blood drawing. Different concentrations of a Gs agonist being prostaglandin E 1 (PGE 1 , ProstinH; 021 mg/ml; Pfizer Inc., NY, USA) or the stable prostacyclin analogue Iloprost (IlomedineH 025 ng/ml; Bayer Schering Pharma AG, Berlin, Germany) were added one minute prior to induction of aggregation with collagen (2 mg/ml). The 50% inhibitory concentration (IC 50 ) was evaluated for each Gs agonist from the patient's response curve and compared to the mean IC 50 measured on platelets of a group of controls (n = 24) for the same agonist [20] . Genetic analysis of GNAS locus DNA was extracted from leukocytes from all patients. Exons 1 to 13 of GNAS were amplified and sequenced using conditions previously described [20] . The presence of STX16 deletions was investigated as described [20, [39] [40] [41] . To rule out the presence of other deletions in the upstream GNAS region, we performed genotyping of different SNPs by PCR and direct sequencing within the NESP55, XL and Exon A/B regions (for overview of all SNPs see Table S1 ).
GNAS, IGF2, H19, SNURF and GRB10 methylation analysis
Genomic DNA (1 ug) was used for bisulfite treatment with the MethylDetector TM bisulfite modification kit (Active Motif, Carlsbad CA) as described [19] .
NESP, XL, Exon A/B and SNURF methylation was studied via Sequenom EpiTYPER technology using primers and conditions already reported [19] . New amplicons to study IGF2, H19 (ICR1 region) and GRB10 regions were designed using the Sequenom EpiDesigner software. Primers and amplicons characteristics are reported in Tables 3 and 4 . All PCR amplifications were performed in triplicate. When the triplicate measurements had a SD equal to or greater than 0.10, all data for the sample involved were discarded (removing 8% of measurements). Sequenom peaks with reference intensity above 2, overlapping and duplicate units were excluded from the analysis.
The sequence and chromosomal location of all amplicons are shown in Figures S1, S2 , S3.
Genetic analysis of IGF2 and SNURF amplicons
To rule out the presence of SNPs that could interfere with the methylation detection sensitivity in the IGF2 and SNURF amplicons, we have screened for the presence of SNPs in the same region that was used for the Sequenom analysis and its surrounding region. A list of all the IGF2 and SNURF SNPs are reported in Tables S2 and S3 that could exclude also deletions in the loci as most patients are heterozygous for the intronic SNPs rs734351 and rs2855523.
Platelet immunoblot analysis
Platelet immunoblot analysis for XLalphas, Gsalphas and CAP-1 was performed as described [20] Platelets isolated from citrated blood were directly lysed in ice-cold PBS containing 1% igepal CA-630 (Sigma Chemical, St. Louis, MO), 2 mmol/liter Na 3 VO 4 , 1 mmol/liter EDTA, 1 mmol/liter phenylmethylsulfonyl fluoride, 2 mmol/liter dithioerythreitol, 1% aprotinin, and 2 mmol/liter NaF, and incubated on ice for 60 min. Platelet extracts (50 mg) were mixed with Laemmli sample buffer and resolved by SDS/ PAGE. Blots were revealed with a monoclonal anti-Gsa antibody [42] a monoclonal anti-XLas antibody (11F7) [43] or a monoclonal anti-CAP1 antibody as loading control (Santa Cruz Biotechnology Inc.). Bands were quantified using the Java image processing program ImageJ 1.34 g (NIH Image software).
Statistical analysis
Average of CpGs methylation for each amplicon was calculated for both controls and patients samples. Statistical analysis was performed using PRISM 5.0a software. Two-tailed unpaired Ttest (p,0.05) was used to study group methylation differences between PPHP patients and healthy controls for all the imprinting control regions studied and to evaluate protein expression differences.
A more individual statistical approach was then performed comparing each patient's Sequenom CpG value or amplicon average with the distribution of values of the same variable measured in a group of healthy controls (n = 41 for NESP, n = 48 for XL and GRB10, n = 47 for Exon A/B, n = 45 for IGF2, n = 33 for H19, n = 35 for SNURF) (Z-test, P,0.05). Values with a Zscore #22 and $+2 were considered significantly hypo-or hypermethylated, respectively. Normality test was assessed with SPSS 12.5 software to study the control population values distribution.
Results
Platelet Gs function
We studied platelet Gs activity in 13 PPHP patients with variable AHO features as reported in Table 2 . For patients 1 to 4 platelet testing could not be performed since only a DNA sample was available for further analysis. When platelet aggregation was induced with collagen in the patients, after preincubation with either prostaglandin E1 (Prostin) or a stable prostacyclin analogue (Iloprost), significantly higher concentrations of both Gs agonists were required to achieve the 50% inhibition of platelet aggregation (IC 50 ), as compared to the healthy controls. This platelet aggregation-inhibition Gs test was performed in 24 healthy controls and we compared their mean IC 50 values for patients.
Genetic analysis of GNAS
Since our patients with an AHO-like phenotype were clinically diagnosed as having PPHP or POH (only for patient 5) and had platelet Gs hypofunction, GNAS screening for inactivation mutations was performed using leukocyte gDNA for sequencing the PCR amplified 13 exons, including exon/intron boundaries. No GNAS coding mutations were found in any of the patients. All patients were heterozygous for at least one of the studied GNAS region SNPs, excluding small chromosomal deletions within the GNAS cluster (Table S1 ). In addition, patients 5 to 17 were previously studied for copy number variants within the GNAS locus or its surrounding region and found to be negative [44] .
Study of GNAS methylation
GNAS methylation was screened for the three amplicons NESP, XL and ExonA/B using the Sequenom EpiTYPER as we previously optimized for PHP-Ib and PHP-Ia cases [19] . We could observe a significant hypermethylation for the XL amplicon in patients vs. controls (3663 vs. 2963% (mean6SD); T-test, p,0.001; Figure 1A ). Interestingly, this is the opposite pattern of the methylation defect described for PHP-Ib and PHP-Ia patients having pronounced XL hypomethylation [19] . Overall methylation that includes all studied CpGs in the amplicons for NESP and ExonA/B did not show any significant difference between patients and controls ( Figure 1A ) though some separate patients (patient 1, 2 and 3 for NESP and patient 3 and 5 for ExonA/B) showed a significant difference in overall methylation (Figure 2A) . However, the study of single CpGs within these amplicons showed significant hyper-(red) or hypo-(green) methylation (Z-test, p,0.05) for both the NESP and ExonA/B amplicons and for almost all patients (Figure 2A) . Based on the analysis of the single CpGs in NESP and ExonA/B (not for XL), some patients seemed to cluster in subgroups but these clusters did not correlate further with the clinical severity of AHO phenotype.
Study of XLalphaS and Gsalpha expression in platelets
To evaluate whether the XL hypermethylation would be associated with decreased XLalphaS expression, immunoblot analysis was performed using platelet extracts as we previously also did for a PHP-Ib patient with XL hypomethylation and increased XLalphaS levels in platelets [41] . We have studied XLalphaS and Gsalpha expression in platelets from 11 of the 17 patients and 5 healthy controls (Figure 3) . While Gsalpha was not statistically different between patients and controls, XLalphaS showed a significant decreased expression (58632 vs. 100619, respectively. T-test, p,0.05).
Study of IGF2 and H19 ICR1 methylation
We next studied 30 CpGs in the DMR1 of IGF2 and 25 CpGs in the ICR1 of the H19 locus ( Table 3 for their precise  chromosomal location) . Surprisingly, we could observe significant hypermethylation of the IGF2 amplicon in patients vs. controls (20610 vs. 1467%; T-test, p,0.05; Figure 1B) . The overall CpG methylation for the H19 amplicon was not significantly different for patients and controls (3568 vs. 3565%), though a significant overall hypermethylation was observed for patients 2 and 4 ( Figure 2B) . For the methylation analysis of single CpGs within the IGF2 amplicon, we could observe a significant hypermethylation in 14 out of 17 PPHP patients at specific CpGs ( Figure 2B ) (Z-test, p,0.05). For the H19 region also some specific CpGs show significant differences in methylation but only for a few patients and clustering within patients seemed not be present. Spearman correlation between IGF2 methylation and height of patients was not significant.
Study of SNURF methylation
The amplicon for SNURF included 18 CpGs and a significant hypomethylation in the SNURF amplicon was found for patients vs. controls (2366 vs. 3266%; T-test, p,0.001; Figure 1C) . Remarkably, single CpG analysis showed both significant hyper (CpG7_8) and hypo (CpG14_16, CpG25) methylation ( Figure 2C ) within the same amplicon and for almost all patients. This dual pattern was not observed in any of the normal control subjects. Spearman correlation between SNURF methylation and weight of patients was not significant.
Study of GRB10 methylation
The amplicon for the GRB10 region included 18 CpGs and their methylation did not appear to be significantly different between patients and controls (3767 vs. 3466%; Figure 1C) . Interestingly, the overall methylation for patients 1 and 2 showed a significant GRB10 hypermethylation of 56 and 50%, respectively, vs. 3566% for controls (Z-test, p,0.05) ( Figure 2C ). The analysis of single CpGs showed some significant differences for some patients with both hyper-and hypomethylated sites ( Figure 2C ).
Discussion
The human GNAS cluster contains three differentially methylated regions: NESP, XL and exon A/B [19] . Patients who develop PHPIb usually present with exon A/B hypomethylation [14, [45] [46] [47] . In these familial PHP-Ib cases the latter appears to be caused by maternally inherited deletions affecting either the STX16 [39, 48] or the NESP55/NESPAS regions [40, 49, 50] . Broader GNAS imprinting defects involving the three differentially methylated GNAS regions are always observed in sporadic PHP-Ib cases with NESP55 hypermethylation versus XL and exon A/B hypomethylation [19, 46, [51] [52] [53] . Recently, a similar broad epigenetic GNAS defect was described for some PHP-Ia cases without GNAS coding mutations [15, 16, 18, 19] . These patients had PTH resistance but also an AHO phenotype implicating that GNAS methylation defects could also result in AHO features. We therefore hypothesize that patients with an AHO-like phenotype but no endocrine abnormalities and still having functional Gs hypofunction (often referred to as PPHP) could present with GNAS methylation abnormalities if coding GNAS mutations are also excluded. We studied GNAS methylation in 16 patients with clinical diagnosis of PPHP and 1 POH patient without GNAS mutations but having platelet Gs hypofunction and an AHO phenotype that mainly involves short stature and brachydactyly and/or other types of bone abnormalities. GNAS methylation was quantified for the three differentially methylated regions using the Sequenom EpiTYPER as we previously did for PHP-Ib and PHP-Ia cases [19] . Grouped analysis showed a significant hypermethylation for the XL amplicon in PPHP patients versus controls (36% vs 29%; p,0.001) but overall methylation for the NESP and ExonA/B regions was not significantly different between patients and controls, except for significant hypermethylation in patients 1, 2 and 3 for NESP and patients 3 and 5 for ExonA/B. The same trend for hypermethylation in NESP and ExonA/B is also visible when analyzing separate CpGs for at least the first 10 patients while the other 7 patients show a weak trend towards hypomethylation of NESP and ExonA/B. This peculiar methylation pattern (with hypermethylation of NESP, XL and ExonA/B) is different from the imprinting pattern observed in PHP-Ib and PHP-Ia patients (having NESP hyper versus XL and Exon A/B hypomethylation).
The main defect in our patients is the significant XL hypermethylation that could be linked to their Short for Gestational Age (SGA) and shortness phenotype. Interestingly, it is known that the main phenotype for XLalphaS deficient mice is the regulation of postnatal growth with neonatal feeding problems, leanness, inertiae and a high mortality rate [54] . Postnatally, changes in the expression pattern of XLalphaS in different tissues have been also characterized, as surviving mice develop into healthy and fertile adults, which are however characterized by leanness despite elevated food intake [55] . In addition, GNAS deletions including the XL region have been identified in some patients with severe pre-and/or postnatal growth retardation as well as feeding difficulties [56, 57] . We also found that the XL hypermethylation in the patients was associated with decreased XLalphaS protein levels in their platelets. Further studies will be needed to evaluate whether this decreased expression of XLalphaS could also be responsible for the platelets Gs hypofunction in these patients. We have previously shown that XLalphas can regulate platelet Gs activity [43, 58] , data that have been further supported by studies in other cells [59] [60] [61] .
Some typical AHO features are also present in patients with other imprinting syndromes such as for the growth and neurodevelopmental diseases Silver-Russel, Beckwith-Wiedemann, Prader-Willi and Angelman syndromes. In addition, IGF2, H19 and GRB10 together with GNAS have been described to be part of an imprinted gene network that regulate embryonic growth and differentiation dependent on Zac-1 regulation in mice [27] . Therefore, we have also studied the methylation of other imprinted genes such as IGF2, H19, SNURF and GRB10. Surprisingly, we could observe significant hypermethylation for IGF2 (20 vs. 10%; P,0.05) and hypomethylation (23 vs. 32; P,0.001) for SNURF while H19 and GRB10 showed no overall differences between patients and controls. The physiological relevance of these findings in relation to the clinical phenotypes remains to be studied. However, some other groups already reported so-called multilocus methylation abnormalities (e.g. for Beckwith-Wiedemann syndrome [62] and Silver-Russel syndrome [63, 64] ). In all these reports somatic mosaicism has been proposed to explain the patients epigenotypes as result of a post-zygotic error of imprint setting. Interestingly, a similar overall methylation defect has been recently described in patients with growth and development problems [65] [66] [67] .
Mutations in a trans-acting factor involved in establishing or maintaining methylation at multiple chromosomal loci however could also explain the presence of such overall methylation abnormalities. The latter hypothesis has been demonstrated in the Beckwith-Wiedemann syndrome [68] , transient neonatal diabetes [69] and the Immunodeficiency-Centromeric instability-Facial anomalies (ICF) syndrome [70] . A similar mechanism has also been recently postulated to exists for PHPIb cases [71] but this remain to be proven. The methylation changes observed in our patients seem to affect mainly maternally methylated regions as XL, IGF2 and SNURF are paternally expressed genes (see Figures S1, S2, S3 ). In conclusion we studied GNAS, IGF2, H19, SNURF and GRB10 methylation in patients with and AHO-like phenotype and Gs hypofunction but no GNAS coding mutations. We could broaden the spectrum of (epi)genetic defects associated with an AHO phenotype by identifying an epigenetic defect in XL, IGF2 and SNURF in 16 PPHP patients and 1 POH case. More studies on multiple imprinting control regions in more PPHP patients are warranted to further investigate the combination of epigenetic defects in relation to phenotypes. Table S1 (XLSX) 
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